Skip to main content
. 2022 Apr 5;10(4):e003765. doi: 10.1136/jitc-2021-003765

Figure 3.

Figure 3

Neoantigens, immune responses and immunoediting. The number of SNVs (A), predicted neoantigens (p-neoAgs) (B), and expressed neoantigens (e-neoAgs) (C), the ratio of p-neoAg to missense mutation (D), and the neoantigen expression ratio (e-neoAg/p-neoAg) (E) in the eight groups. (F) and G) Cytolytic activity score (CYT) and IFN-γ TPM. (H) MHC class I score calculated based on HLA-A, HLA-B, and HLA-C TPM. PD-L1 TPS (I) and CD274 (PD-L1) TPM (J) in the eight groups. NK cell score inferred from xCell (K). Percentages of CD3+ (L) and CD39+CD103+CD8+ cells (M) in FTD detected by flow cytometry. (N) Fold-change of IFN-γ concentration (TILs plus FTD/TILs only). IFN, interferon; FTD, fresh tumor digests; NK, natural killer; ns, not significant; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SNVs, single nucleotide variants; TIL, tumor-infiltrating lymphocytes; TPM, transcripts per million; TPS, Tumor Proportion Score. *p<0.05; **p<0.01; ***p<0.001.